News News

January 17, 2021 Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma, Company Expects to Report Initial Clinical Data in 2021

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

December 20, 2020 Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

December 3, 2020 Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

October 22, 2020 Sirnaomics Sealed US$105 Million Series D Financing to Fund Development of RNAi Therapeutics for Treatment of Cancers, Fibrotic Diseases and Viral Infections

Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it…

August 27, 2020 Sirnaomics Publishes Preclinical Study of Novel siRNA-Gemcitabine Conjugate for Advancing RNAi Therapeutics to Treat Multiple Types of Cancers

Sirnaomics, Inc. , a leading biopharmaceutical company in discovery and development of RNAi therapeutics for treatment of cancer…

August 24, 2020 RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announces today…

1 2 3 4 5 11